Related Experiment Video
Updated: Oct 22, 2025

Author Spotlight: Hypothalamic Neural Mechanism Insights
Published on: August 4, 2023
Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target
Couvineau Alain1, Nicole Pascal1, Gratio Valérie1
1INSERM UMR1149/Inflammation Research Center (CRI), Team "From Inflammation to Cancer in Digestive Diseases" Labeled by "la Ligue Nationale Contre le Cancer", University of Paris, DHU UNITY, 75018 Paris, France.
Orexin neuropeptides and their receptors are crucial for wakefulness and other bodily functions. This system shows promise as a therapeutic target for various cancers.
Area of Science:
- Neuroscience
- Endocrinology
- Oncology
Background:
- Orexin neuropeptides (Orexin-A/hypocretin-1 and Orexin-B/hypocretin-2) and their receptors (OX1R and OX2R) are key regulators of wakefulness, appetite, and homeostasis.
- Dysregulation of the orexin system is implicated in narcolepsy, metabolic syndrome, and cancer.
- Orexin receptors, particularly OX1R, are expressed in various cancer types, including colon, pancreas, and prostate cancers.
Purpose of the Study:
- To review the intricate relationship between the orexin system and cancer.
- To explore the potential of the orexin/OX1R system as a therapeutic target in oncology.
Main Methods:
- Literature review of studies investigating the orexin system and its role in cancer biology.
- Analysis of research on OX1R expression and function in tumor cells.
Main Results:
- The orexin/OX1R system plays a significant role in regulating physiological processes.
- OX1R expression in cancer cells suggests a potential role in tumor progression.
- OX1R exhibits proapoptotic activity in tumor cells, indicating therapeutic potential.
Conclusions:
- The orexin/OX1R system represents a promising and emerging target for cancer therapy.
- Further research is warranted to fully elucidate the therapeutic applications of targeting this system in oncology.
Related Concept Videos
Regulation of Food Intake
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle

